Book contents
- Fetal Therapy
- Fetal Therapy
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Section 1: General Principles
- Section 2: Fetal Disease: Pathogenesis and Treatment
- Red Cell Alloimmunization
- Chapter 10 Management of Red Cell Alloimmunization
- Chapter 11 Fetal and Neonatal Alloimmune Thrombocytopenia: Clinical Disease and Management
- Structural Heart Disease in the Fetus
- Fetal Dysrhythmias
- Manipulation of Fetal Amniotic Fluid Volume
- Fetal Infections
- Fetal Growth and Well-being
- Preterm Birth of the Singleton and Multiple Pregnancy
- Complications of Monochorionic Multiple Pregnancy: Twin-to-Twin Transfusion Syndrome
- Complications of Monochorionic Multiple Pregnancy: Fetal Growth Restriction in Monochorionic Twins
- Complications of Monochorionic Multiple Pregnancy: Twin Reversed Arterial Perfusion Sequence
- Complications of Monochorionic Multiple Pregnancy: Multifetal Reduction in Multiple Pregnancy
- Fetal Urinary Tract Obstruction
- Pleural Effusion and Pulmonary Pathology
- Surgical Correction of Neural Tube Anomalies
- Fetal Tumors
- Congenital Diaphragmatic Hernia
- Fetal Stem Cell Transplantation
- Gene Therapy
- Section III: The Future
- Index
- References
Chapter 10 - Management of Red Cell Alloimmunization
from Red Cell Alloimmunization
Published online by Cambridge University Press: 21 October 2019
Book contents
- Fetal Therapy
- Fetal Therapy
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Section 1: General Principles
- Section 2: Fetal Disease: Pathogenesis and Treatment
- Red Cell Alloimmunization
- Chapter 10 Management of Red Cell Alloimmunization
- Chapter 11 Fetal and Neonatal Alloimmune Thrombocytopenia: Clinical Disease and Management
- Structural Heart Disease in the Fetus
- Fetal Dysrhythmias
- Manipulation of Fetal Amniotic Fluid Volume
- Fetal Infections
- Fetal Growth and Well-being
- Preterm Birth of the Singleton and Multiple Pregnancy
- Complications of Monochorionic Multiple Pregnancy: Twin-to-Twin Transfusion Syndrome
- Complications of Monochorionic Multiple Pregnancy: Fetal Growth Restriction in Monochorionic Twins
- Complications of Monochorionic Multiple Pregnancy: Twin Reversed Arterial Perfusion Sequence
- Complications of Monochorionic Multiple Pregnancy: Multifetal Reduction in Multiple Pregnancy
- Fetal Urinary Tract Obstruction
- Pleural Effusion and Pulmonary Pathology
- Surgical Correction of Neural Tube Anomalies
- Fetal Tumors
- Congenital Diaphragmatic Hernia
- Fetal Stem Cell Transplantation
- Gene Therapy
- Section III: The Future
- Index
- References
Summary
Red cell alloimmunization in pregnancy, or hemolytic disease of the fetus and newborn (HDFN), has long been a major cause of perinatal morbidity and mortality. No antenatal treatment was available up to the 1960s and the only option was thus (preterm) induction, to enable neonatal treatment. This changed with the introduction of intrauterine intraperitoneal transfusion in 1963, although the complication risk of these and the later introduced ultrasound-guided intravascular transfusions long remained substantially high.
- Type
- Chapter
- Information
- Fetal TherapyScientific Basis and Critical Appraisal of Clinical Benefits, pp. 91 - 98Publisher: Cambridge University PressPrint publication year: 2020
References
Bowman, JM, Pollock, JM, Penston, LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986; 51: 117–21.Google Scholar
Nederlandse Vereniging voor Obstetrie & Gynaecologie (NVOG) (2009). Erytrocytenimmunisatie en zwangerschap: Versie 2.1. https://www.nvog.nl/wp-content/uploads/2018/03/Erytrocytenimmunisatie-en-zwangerschap_.pdfGoogle Scholar
Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol. 2017; 130: e57–70.Google Scholar
Qureshi, H, Massey, E, Kirwan, D, Davies, T, Robson, S, White, J, Jones, J, Allard, S, British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014; 24: 8–20.Google Scholar
Levine, P. Serological factors as possible causes in spontaneous abortions. J Hered. 1943; 34: 71–80.Google Scholar
Zwiers, C, Koelewijn, JM, Vermij, L, van Sambeeck, J, Oepkes, D, de Haas, M, van der Schoot, CE. ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. Transfusion. 2018; 58: 1611–17.CrossRefGoogle ScholarPubMed
Royal College of Obstetricians and Gynaecologists (2014). Green-top Guideline 65: The Management of Women with Red Cell Antibodies during Pregnancy. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg65Google Scholar
ACOG. Practice Bulletin No. 192: Management of alloimmunization during pregnancy. Obstet Gynecol. 2018; 131: e82–90.Google Scholar
Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2018). Draaiboek prenatale screening infectieziekten en erytrocytenimmunisatie: Versie 6.0. https://www.rivm.nl/documenten/draaiboek-prenatale-screening-infectieziekten-en-erytrocytenimmunisatieGoogle Scholar
National Blood Authority Australia (2015). Patient Blood Management Guidelines: Module 5 Obstetrics and Maternity. https://www.blood.gov.au/pbm-module-5Google Scholar
Centraal Begeleidingsorgaan (2011). Richtlijn Bloedtransfusie. http://nvb-trip-symposium.nl/wp-content/uploads/2017/08/Richtlijnbloedtransfusie2011.pdfGoogle Scholar
Koelewijn, JM, de Haas, M, Vrijkotte, TG, Bonsel, GJ, van der Schoot, CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008; 48: 1721–9.Google Scholar
Mayne, S, Parker, JH, Harden, TA, Dodds, SD, Beale, JA. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ. 1997; 315: 1588.Google Scholar
van der Ploeg, CPB, Schönbeck, Y, Oomen, P, Vos, K. Prenatale Screening Infectieziekten en Erytrocytenimmunisatie (PSIE) Procesmonitor 2015. Bilthoven: RIVM, TNO, 2017.Google Scholar
Hendrickson, JE, Delaney, M. Hemolytic Disease of the fetus and newborn: modern practice and future Investigations. Transfus Med Rev. 2016; 30: 159–64.Google Scholar
Scheffer, PG, van der Schoot, CE, Page-Christiaens, GC, de Haas, M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG. 2011; 118: 1340–8.Google Scholar
Slootweg, YM, Lindenburg, IT, Koelewijn, JM, van Kamp, IL, Oepkes, D, de Haas, M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018; 219: 393.e1–393.e8.Google Scholar
van Dijk, BA, Dooren, MC, Overbeeke, MA. Red cell antibodies in pregnancy: there is no ‘critical titre’. Transfus Med. 1995; 5: 199–202.Google Scholar
Oepkes, D, van Kamp, IL, Simon, MJ, Mesman, J, Overbeeke, MA, Kanhai, HH. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol. 2001; 184: 1015–20.CrossRefGoogle ScholarPubMed
Zwiers, C, van Kamp, I, Oepkes, D, Lopriore, E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Rev Hematol. 2017; 10: 337–44.Google Scholar
Mari, G, Deter, RL, Carpenter, RL, Rahman, F, Zimmerman, R, Moise, KJ Jr., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative group for Doppler assessment of the blood velocity in anemic fetuses. N Engl J Med. 2000; 342: 9–14.Google Scholar
Zimmerman, R, Carpenter, RJ Jr., Durig, P, Mari, G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG. 2002; 109: 746–52.Google Scholar
Oepkes, D, Brand, R, Vandenbussche, FP, Meerman, RH, Kanhai, HH. The use of ultrasonography and Doppler in the prediction of fetal haemolytic anaemia: a multivariate analysis. Br J Obstet Gynaecol. 1994; 101: 680–4.Google Scholar
Chitkara, U, Wilkins, I, Lynch, L, Mehalek, K, Berkowitz, RL. The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies. Obstet Gynecol. 1988; 71: 393–8.Google Scholar
Dukler, D, Oepkes, D, Seaward, G, Windrim, R, Ryan, G. Noninvasive tests to predict fetal anemia: a study comparing Doppler and ultrasound parameters. Am J Obstet Gynecol. 2003; 188: 1310–14.CrossRefGoogle ScholarPubMed
Oepkes, D, Seaward, PG, Vandenbussche, FP, Windrim, R, Kingdom, J, Beyene, J, Kanhai, HH, Ohlsson, A, Ryan, G, DIAMOND Study Group. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006; 355: 156–64.Google Scholar
Bang, J, Bock, JE, Trolle, D. Ultrasound-guided fetal intravenous transfusion for severe rhesus haemolytic disease. BMJ (Clin Res Ed). 1982; 284: 373–4.Google Scholar
Moise, KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008; 112: 164–76.Google Scholar
Nicolaides, KH, Soothill, PW, Clewell, WH, Rodeck, CH, Mibashan, RS, Campbell, S. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet. 1988; 1: 1073–5.Google Scholar
Society for Maternal-Fetal Medicine, Mari, G, Norton, ME, Stone, J, Berghella, V, Sciscione, AC, Tate, D, Schenone, MH. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia – diagnosis and management. Am J Obstet Gynecol. 2015; 212: 697–710.CrossRefGoogle Scholar
Adama van Scheltema, PN, Borkent, S, Sikkel, E, Oepkes, D, Vandenbussche, FP. Fetal brain hemodynamic changes in intrauterine transfusion: influence of needle puncture site. Fetal Diagn Ther. 2009; 26: 131–3.Google Scholar
Moise, KJ Jr., Carpenter, RJ Jr., Kirshon, B, Deter, RL, Sala, JD, Cano, LE. Comparison of four types of intrauterine transfusion: effect on fetal hematocrit. Fetal Ther. 1989; 4: 126–37.Google Scholar
Zwiers, C, Lindenburg, ITM, Klumper, FJ, de Haas, M, Oepkes, D, Van Kamp, IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017; 50: 180–6.Google Scholar
Detti, L, Oz, U, Guney, I, Ferguson, JE, Bahado-Singh, RO, Mari, G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol. 2001; 185: 1048–51.Google Scholar
Weiner, CP, Williamson, RA, Wenstrom, KD, Sipes, SL, Widness, JA, Grant, SS, Estle, L. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. Am J Obstet Gynecol. 1991; 165: 1302–7.Google Scholar
Scheier, M, Hernandez-Andrade, E, Fonseca, EB, Nicolaides, KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006; 195: 1550–6.Google Scholar
Tiblad, E, Kublickas, M, Ajne, G, Bui, TH, Ek, S, Karlsson, A, Wikman, A, Westgren, M. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011; 30: 266–73.Google Scholar
Pasman, SA, Claes, L, Lewi, L, Van Schoubroeck, D, Debeer, A, Emonds, M, Geuten, E, De Catte, L, Devlieger, R. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven. Facts Views Vis Obgyn. 2015; 7: 129–36.Google Scholar
Sainio, S, Nupponen, I, Kuosmanen, M, Aitokallio-Tallberg, A, Ekholm, E, Halmesmäki, E, Orden, MR, Palo, P, Raudaskoski, T, Tekay, A, Tuimala, J, Uotila, J, Stefanovic, V. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015; 94: 383–90.Google Scholar
Lindenburg, IT, Wolterbeek, R, Oepkes, D, Klumper, FJ, Vandenbussche, FP, van Kamp, IL. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther. 2011; 29: 307–14.Google Scholar
Zwiers, C, Oepkes, D, Lopriore, E, Klumper, FJ, De Haas, M, van Kamp, IL. The near disappearance of fetal immune hydrops in relation to current state‐of‐the‐art management of red cell alloimmunization. Prenat Diagn. 2018; 38: 943–50.Google Scholar
van Kamp, IL, Klumper, FJ, Bakkum, RS, Oepkes, D, Meerman, RH, Scherjon, SA, Kanhai, HH. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol. 2001; 185: 668–73.Google Scholar
Ree, IMC, Smits-Wintjens, V, van der Bom, JG, van Klink, JMM, Oepkes, D, Lopriore, E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017; 10: 607–16.Google Scholar
Lindenburg, IT, Smits-Wintjens, VE, van Klink, JM, Verduin, E, van Kamp, IL, Walther, FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012; 206: 141. e1–8.Google Scholar
Zwiers, C, van der Bom, JG, van Kamp, IL, van Geloven, N, Lopriore, E, Smoleniec, J, et al. Postponing Early Intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018; 219: e1–291. e9.Google Scholar
Bowman, JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991; 34: 296–303.CrossRefGoogle ScholarPubMed
Giannina, G, Moise, KJ Jr., Dorman, K. A simple method to estimate volume for fetal intravascular transfusions. Fetal Diagn Ther. 1998; 13: 94–7.Google Scholar
- 1
- Cited by